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• Six patients inquired about CBD use during my first week at
Brookfield Family Medicine in Brookfield, CT
• Patients reported hearing claims that it was beneficial for
many conditions including arthritis, anxiety/depression, and
chronic pain
• Many questioned the legality of CBD in the state of
Connecticut

2A. PROBLEM
IDENTIFIC ATION

• A CBD retailer had been operating over a year within a
mile of the clinic
• One provider at the practice told me he had recently had
four patients in one day ask about CBD
• According the CDC, 23% of all adults in the US have some
form of arthritis and more than 1 in 4 adults with arthritis
report suffering from severe joint pain1
• Data from Anxiety and Depression Association of America
reports that 40 million adults in the US suffer from an anxiety
disorder2
• An estimated 1 in 5 adults in the US had chronic pain in 2016
according to a report from the CDC3

• CBD has become a popular consumer product over
the last decade, especially as American consumers
increasingly want more complementary and
alternative medicines4

2B.
DESCRIPTION
OF NEED

• However, CBD is not federally regulated and a 2017
article from JAMA showed only 30% of CBD
products were labelled accurately5
• Past UVM students have made pamphlets on patient
education of CBD in Vermont, but there hasn’t been
a pamphlet made specifically for consumers in
Connecticut where regulations and need may differ14
• In addition, there is a lack of general public
understanding regarding the efficacy, safety, and
legality of this increasingly popular product

Arthritis contributes to $140 billion in direct medical
costs annually1

Chronic pain contributes to $550 billion in direct
medical costs each year in the US3

3 A. PUBLIC H E ALTH
AND COST
CONSIDE RATI ON S

According to the National Institutes of Mental Health,
National Survey on Drug Use and Health (NSDUH) in
2016, it is estimated that 300,000 people in CT live with
MDD, schizophrenia, or bipolar disorder7

The average cost of Anxiety annually in the US is
between $42.3 billion and $46.6 billion with over 75%
attributed to indirect costs2

4. COMMUNITY PERSPECTIVE ON ISSUE
AND SUPPORT FOR PROJECT
• “I do have a few patients who ask about it (CBD)… it is increasing… I mean 10 years ago no one
was asking about it and now I’m starting to see it on patient’s med lists. Even I bought hemp
shampoo/conditioner for my dog. Patients usually have questions for me like ‘is it safe? Do you
think it works?’ Honestly, I don’t feel completely comfortable counseling them on it (CBD). I
usually recommend looking up an honest website.”
- Jessica Stellato, APRN, Family Practice Nurse Practitioner

• “I have 2 to 3 patients ask about it per week. 5 years ago no one asked about and now patients
have a lot of questions about safety and whether it will be helpful for their specific complaint,
things like pain… anxiety… I think there’s some data that it isn’t that helpful for
anxiety/depression. I try to make them realize that this isn’t highly regulated, and patients need to
take that into consideration. “
- Dr. Julia Auerbach, MD, Family Medicine Physician

5. INTERVENTION
AND METHODOLOGY
• A pamphlet was created to educate patients on CBD use in
Connecticut. This pamphlet included information on:
• What CBD is and how it is derived from hemp
• Current legality status of CBD in the state of Connecticut
• The validity of claims of CBD as backed by peer-reviewed research
• Considerations when purchasing CBD
• Answers to frequently asked questions
• Pamphlet was shared with the providers at the Brookfield Family
Medicine Clinic and gone over in detail so they could properly educate
patients on the use of CBD

• Pamphlet was made available to the providers at
Brookfield Family Medicine. It was also distributed to
the head of Family Medicine for the health network

6. RESULTS
AND
RESPONSES

• Responses from providers and patients was positive
• Providers appreciated having more information
readily available to them when counseling patients
on the pros and cons of CBD use

• Patients appreciated having information that they
could take home with them
• No formal data was collected from patients about
the efficacy or quality of the pamphlet

• No formal data was collected on the effectiveness of the provided
pamphlet due to time limitations
• Future surveys can guide what information should be in the pamphlet
and what information may not be helpful
• There are many limitations regarding the effectiveness of the pamphlet
• The pamphlet was only provided in English and may be inaccessible to
non-English speakers

• Future data collected can help guide who this pamphlet should be
distributed to. Now, it’s given to those who ask about CBD but there
may be patients who use CBD and are not disclosing this with their
providers
• The pamphlet will need periodic updating as new data is published

7. EVALUATION
OF
EFFECTIVENESS
AND
LIMITATIONS

8.
RE COMME NDATI O NS
FOR FUTURE
PROJE CTS

Distribute

Distribute the pamphlet to other primary care and specialty
clinics within Connecticut

Provide

Provide a brief survey on knowledge of CBD to taken by
patients before and after they read the pamphlet to evaluate
effectiveness of the educational materials

Update

Update the pamphlet bi-annually to ensure the information
remains up-to-date

Check in

Check in with the clinics using the pamphlet to ensure it is
still being distributed to patients and if they are continually
finding it helpful
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